Medazepam

Summary

Medazepam (CHEMBL28333) is an approved small molecule (ATC N05BA03); indicated across 1 condition including anxiety.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05BA03
• Indications: 1 condition
• Chemistry: 270.75 Da · C16H15ClN2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL28333
Name	Medazepam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4041
ATC	N05BA03
Molecular formula	C16H15ClN2
Molecular weight	270.75
InChIKey	YLCXGBZIZBEVPZ-UHFFFAOYSA-N

SMILES: CN1CCN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3

IUPAC name: 7-chloro-1-methyl-5-phenyl-2,3-dihydro-1,4-benzodiazepine

Also known as: Medazepam, Nobrium, Pamnace, SID26757942, SID144206658, MEDAZEPAM, medazepam

Parent form; salt/anhydrous children: CHEMBL2106842

Patent coverage: 2,419 distinct patent families (6,650 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,625 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Neuronal acetylcholine receptor subunit alpha-4, GABA-A receptor; anion channel, 5-hydroxytryptamine receptor 2C, Alpha-1A adrenergic receptor, Prostaglandin G/H synthase 2, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, Adenosine receptor A3, 3’,5’-cyclic-AMP phosphodiesterase 4D, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
O09028	6.28	Ki	528	nM	CHEMBL_ACT_458157
OPRK1	6	AC50	990	nM	CHEMBL_ACT_25129818
P62813	5.68	AC50	2100	nM	CHEMBL_ACT_25131009
NR1I2	5.51	AC50	3100	nM	CHEMBL_ACT_25188482
PDE4D	5.28	AC50	5200	nM	CHEMBL_ACT_25185758

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
anxiety	4	MONDO:0011918	EFO:0005230

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).